Immune Responses in Malaria

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2017 Apr 9

PMID 28389518

Citations 31

Authors

Carole A Long

Fidel Zavala

Affiliations

Soon will be listed here.

Abstract

Evidence accumulated through the years clearly indicates that antiparasite immune responses can efficiently control malaria parasite infection at all development stages, and under certain circumstances they can prevent parasite infection. Translating these findings into vaccines or immunotherapeutic interventions has been difficult in part because of the extraordinary biological complexity of this parasite, which has several developmental stages expressing unique sets of stage-specific genes and multiple antigens, most of which are antigenically diverse. Nevertheless, in the last 30 years major advances have resulted in characterization of a number of vaccine candidates, exploration of the repertoire of host immune responses to the various parasite stages, and also identification of significant hurdles that need to be overcome. Most important, these advances strengthened the concept that the induction of host immune responses that target all developmental stages of can efficiently control or abrogate infections and strongly support the notion that an effective vaccine can be developed. This vaccine would be a critical component for programs aimed at controlling or eradicating malaria.

Citing Articles

Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs.

Frooman M, Choi K, Kahn M, Yang L, Cunningham A, RisCassi J Sci Rep. 2025; 15(1):8614.

PMID: 40074802 PMC: 11903679. DOI: 10.1038/s41598-025-92191-6.

A systematic review and meta-analysis of blood level of MCP-1/CCL-2 in severe and uncomplicated malaria.

Kotepui M, Kwankaew P, Mahittikorn A, Kotepui K, Masangkay F, Wattanapisit A Sci Rep. 2024; 14(1):28738.

PMID: 39567619 PMC: 11579328. DOI: 10.1038/s41598-024-80201-y.

A Head-to-Head Comparative Study of the Replication-Competent Vaccinia Virus and AAV1-Based Malaria Vaccine versus RTS,S/AS01 in Murine Models.

Zainal K, Hasyim A, Yamamoto Y, Mizuno T, Sato Y, Rasyid S Vaccines (Basel). 2024; 12(10).

PMID: 39460322 PMC: 11512279. DOI: 10.3390/vaccines12101155.

A Plasmodium late liver stage arresting GAP provides superior protection in mice.

Mishra A, Paul P, Srivastava M, Mishra S NPJ Vaccines. 2024; 9(1):193.

PMID: 39424860 PMC: 11489731. DOI: 10.1038/s41541-024-00975-0.

The role of immune-inflammatory markers in children with complicated and uncomplicated malaria in Enugu, Nigeria.

Ugwu A, Chukwuanukwu R, Ehiaghe F, Ugwu E BMC Immunol. 2024; 25(1):47.

PMID: 39039450 PMC: 11265479. DOI: 10.1186/s12865-024-00642-y.

References

Kaushal D, Carter R, Rener J, Grotendorst C, MILLER L, Howard R . Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes. J Immunol. 1983; 131(5):2557-62. View

Guerin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, Beaudoin R . A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature. 1987; 329(6135):164-7. DOI: 10.1038/329164a0. View

Deans J, Alderson T, Thomas A, Mitchell G, Lennox E, Cohen S . Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol. 1982; 49(2):297-309. PMC: 1536485. View

Zavala F, Tam J, Hollingdale M, Cochrane A, Quakyi I, Nussenzweig R . Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985; 228(4706):1436-40. DOI: 10.1126/science.2409595. View

Kapulu M, Da D, Miura K, Li Y, Blagborough A, Churcher T . Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci Rep. 2015; 5:11193. PMC: 4463016. DOI: 10.1038/srep11193. View

Doolan D, Khamboonruang C, Beck H, Houghten R, Good M . Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants. Int Immunol. 1993; 5(1):37-46. DOI: 10.1093/intimm/5.1.37. View

Nardin E, Nussenzweig R, McGregor I, Bryan J . Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science. 1979; 206(4418):597-9. DOI: 10.1126/science.386511. View

Hviid L, Jensen A . PfEMP1 - A Parasite Protein Family of Key Importance in Plasmodium falciparum Malaria Immunity and Pathogenesis. Adv Parasitol. 2015; 88:51-84. DOI: 10.1016/bs.apar.2015.02.004. View

Stowers A, Carter R . Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther. 2001; 1(4):619-28. DOI: 10.1517/14712598.1.4.619. View

10.

Tapchaisri P, Chomcharn Y, Poonthong C, Asavanich A, Limsuwan S, Maleevan O . Anti-sporozoite antibodies induced by natural infection. Am J Trop Med Hyg. 1983; 32(6):1203-8. DOI: 10.4269/ajtmh.1983.32.1203. View

11.

Riley E, Allen S, Bennett S, Thomas P, ODonnell A, Lindsay S . Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans R Soc Trop Med Hyg. 1990; 84(5):648-57. DOI: 10.1016/0035-9203(90)90133-y. View

12.

Zhu J, Hollingdale M . Structure of Plasmodium falciparum liver stage antigen-1. Mol Biochem Parasitol. 1991; 48(2):223-6. DOI: 10.1016/0166-6851(91)90117-o. View

13.

Miura K, Herrera R, Diouf A, Zhou H, Mu J, Hu Z . Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2013; 81(5):1491-501. PMC: 3648006. DOI: 10.1128/IAI.01414-12. View

14.

Reddy K, Amlabu E, Pandey A, Mitra P, Chauhan V, Gaur D . Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci U S A. 2015; 112(4):1179-84. PMC: 4313826. DOI: 10.1073/pnas.1415466112. View

15.

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

16.

Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J . The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 2011; 7(2):e1001276. PMC: 3037350. DOI: 10.1371/journal.ppat.1001276. View

17.

Milner Jr D . Malaria Pathogenesis. Cold Spring Harb Perspect Med. 2017; 8(1). PMC: 5749143. DOI: 10.1101/cshperspect.a025569. View

18.

Doolan D, Houghten R, Good M . Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. Int Immunol. 1991; 3(6):511-6. DOI: 10.1093/intimm/3.6.511. View

19.

Nikolaeva D, Draper S, Biswas S . Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines. 2015; 14(5):653-80. DOI: 10.1586/14760584.2015.993383. View

20.

Saxena A, Singh K, Su H, Klein M, Stowers A, Saul A . The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat Struct Mol Biol. 2005; 13(1):90-1. DOI: 10.1038/nsmb1024. View